Analysis of commercially available snake antivenoms reveals high contents of endotoxins in some products

As injectable therapeutics, snake antivenoms must meet specifications for endotoxin content. The Limulus amebocyte lysate (LAL) test was used to evaluate the endotoxin content in several commercially available antivenoms released for clinical use. It was found that some products have endotoxin conce...

Full description

Saved in:
Bibliographic Details
Published in:Toxicon X 2024-03, Vol.21, p.100187-100187, Article 100187
Main Authors: Solano, Gabriela, Ainsworth, Stuart, Sánchez, Adriana, Villalta, Mauren, Sánchez, Paola, Durán, Gina, Gutiérrez, José María, León, Guillermo
Format: Article
Language:English
Subjects:
Endotoxin
Limulus amebocyte lysate test
Pyrogen
Snake antivenom
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As injectable therapeutics, snake antivenoms must meet specifications for endotoxin content. The Limulus amebocyte lysate (LAL) test was used to evaluate the endotoxin content in several commercially available antivenoms released for clinical use. It was found that some products have endotoxin concentrations higher than the accepted limit for these contaminants. These results emphasize the need to include endotoxin determination as part of the routine evaluation of antivenoms by manufacturers and regulatory agencies. •The Limulus amebocyte lysate test was used to evaluate the endotoxin content in commercially available antivenoms.•Some tested antivenoms contain endotoxin concentrations higher than the accepted limit for these contaminants.•Testing for endotoxin contamination of antivenoms must be routinely performed by manufacturers and regulatory agencies.
ISSN:2590-1710
2590-1710
DOI:10.1016/j.toxcx.2024.100187